期刊
JOURNAL OF IMMUNOLOGY RESEARCH
卷 2019, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2019/5727516
关键词
-
类别
资金
- National Natural Science Foundation of China [30901339, 81172869]
- 1.3.5 Project for Disciplines of Excellence of West China Hospital, Sichuan University [ZYJC18021]
- Application Foundation Project in Sichuan Province [2016JY0021, 2017JY0025]
Chimeric antigen receptor T (CAR-T) cells are T cells engineered to express specific synthetic antigen receptors that can recognize antigens expressed by tumor cells, which after the binding of these antigens to the receptors are eliminated, and have been adopted to treat several kinds of malignancies. Autoimmune diseases (AIDs), a class of chronic disease conditions, can be broadly separated into autoantibody-mediated and T cell-mediated diseases. Treatments for AIDs are focused on restoring immune tolerance. However, current treatments have little effect on immune tolerance inverse; even the molecular target biologics like anti-TNF alpha inhibitors can only mildly restore immune balance. By using the idea of CAR-T cell treatment in tumors, CAR-T cell-derived immunotherapies, chimeric autoantibody receptor T (CAAR-T) cells, and CAR regulatory T (CAR-T) cells bring new hope of treatment choice for AIDs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据